Xigen Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Xigen General Information

Description

Developer of innovative therapeutic peptides designed to be used against inflammation. The company's peptides have metabolic stability, and specificity and are selectively delivered to intracellular targets through proprietary carrier molecules, enabling physicians to treat a broad range of diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Route de la corniche 4
  • 1066 Epalinges
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Route de la corniche 4
  • 1066 Epalinges
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-Feb-2021 Completed Out of Business
5. Later Stage VC (Series B) 16-Nov-2009 Completed Generating Revenue
4. Secondary Transaction - Private 01-Jan-2008 Completed Generating Revenue
3. Early Stage VC (Series A) 06-Sep-2005 Completed Generating Revenue
2. Angel (individual) 19-Jan-2004 Completed Generating Revenue
1. University Spin-Out 01-Jan-2002 Completed Startup
To view Xigen’s complete valuation and funding history, request access »

Xigen Patents

Xigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2013091670-A1 Novel jnk inhibitor molecules for treatment of various diseases Inactive 21-Dec-2011
WO-2012048721-A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Inactive 14-Oct-2010
WO-2012048893-A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Inactive 14-Oct-2010
WO-2011160653-A1 Novel jnk inhibitor molecules Inactive 21-Jun-2010
WO-2011160827-A2 Novel jnk inhibitor molecules Inactive 21-Jun-2010 C07K7/08
To view Xigen’s complete patent history, request access »

Xigen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xigen FAQs

  • When was Xigen founded?

    Xigen was founded in 2002.

  • Where is Xigen headquartered?

    Xigen is headquartered in Epalinges, Switzerland.

  • What is the size of Xigen?

    Xigen has 6 total employees.

  • What industry is Xigen in?

    Xigen’s primary industry is Drug Discovery.

  • Is Xigen a private or public company?

    Xigen is a Private company.

  • What is Xigen’s current revenue?

    The current revenue for Xigen is .

  • How much funding has Xigen raised over time?

    Xigen has raised $40.7M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process